---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000043"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T04:59:18.977052+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NovoCure PANOVA-3 pancreatic cancer trial passes interim DMC review; continues to final analysis

## Summary
- Independent DMC recommended continuation of phase 3 PANOVA-3 trial for unresectable, locally advanced pancreatic cancer.
- Trial evaluating TTFields plus nab-paclitaxel/gemcitabine is fully enrolled; final data expected in 2024.
- No efficacy or safety data disclosed; trial proceeds as planned.

## SEC filing metadata
- accession: 0001645113-23-000043
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000043/0001645113-23-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000043/nvcr-20230721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000043
- JSON: https://secwatch.observer/filing/0001645113-23-000043.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.